ReviewInternational journal of molecular sciences2017
The Immunogenetics of Psoriasis and Implications for Drug Repositioning.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- 2D Visualization of the Psoriasis Transcriptome Fails to Support the Existence of Dual-Secreting IL-17A/IL-22 Th17 T Cells.Frontiers in immunology · 2019Pooled it
- Using siRNA-Based Anti-Inflammatory Lipid Nanoparticles for Gene Regulation in Psoriasis.International journal of nanomedicine · 2025Article
- Cytokine release syndrome induced by anti-programmed death-1 treatment in a psoriasis patient: A dark side of immune checkpoint inhibitors.World journal of clinical cases · 2024Article
- Assessment of the Potential Role of Selected Single Nucleotide Polymorphisms (SNPs) of Genes Related to the Functioning of Regulatory T Cells in the Pathogenesis of Psoriasis.International journal of molecular sciences · 2023Article
- Drug repositioning prediction for psoriasis using the adverse event reporting database.Frontiers in medicine · 2023Article
- Psoriasis: An Immunogenetic Perspective.Global medical genetics · 2022Review
- Skin Microbiome and Treatment-Related Skin Toxicities in Patients With Cancer: A Mini-Review.Frontiers in oncology · 2022Review
- Mechanisms and inhibitors of ferroptosis in psoriasis.Frontiers in molecular biosciences · 2022Review
- Serum interleukin-30 level in patients with psoriasis and its correlation with psoriasis severity: a case-control study.The Journal of international medical research · 2021Article
- Comorbidity in Men with Psoriasis.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2021Article
- Repurposing approved therapeutics for new indication: Addressing unmet needs in psoriasis treatment.Current research in pharmacology and drug discovery · 2021Review
- Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis.Drug delivery and translational research · 2020Article
- The Skin and Gut Microbiome and Its Role in Common Dermatologic Conditions.Microorganisms · 2019Review
- CARD14/CARMA2 Signaling and its Role in Inflammatory Skin Disorders.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a genetically-regulated, T lymphocyte-mediated autoimmune skin disease that causes systemic damage, seriously affecting patient quality of life and survival. Psoriasis treatments, which aim to control the disease's development, are greatly limited because its etiology and pathogenesis have not yet been fully elucidated. A large number of studies have demonstrated that immunogenetic elements are the most important factors responsible for psoriasis susceptibility. This paper delineates the immunogenetic mechanisms of psoriasis and provides useful information with regards to performing drug repositioning for the treatment of psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.